July 5, 2021
Boehringer Ingelheim celebrates 25 years combating PRRS in Europe
Boehringer Ingelheim was celebrating 25 years of partnering with veterinarians and producers to combat porcine reproductive and respiratory syndrome (PRRS) in Europe and more than 25 years in the United States, the company announced last month.
In addition to offering a full range of PRRS modified-live vaccines including Ingelvac® PRRS MLV, Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU, Boehringer Ingelheim is in a unique position to offer a holistic approach to PRRS control through collaborative research, innovative diagnostics and services, the company said.
Martin Forchieri, head of vaccine franchise (swine business) at Boehringer Ingelheim, said: "All too often the term "journey" is used for what merely turns out to be projects – with regards to Ingelvac®PRRS MLV though, it has been and continues to be a learning journey at its best. Over the last 25 years, both Boehringer Ingelheim, as well as the swine industry, have learned so much about how to best control and prevent PRRS. Harvesting such learning contributes to better PRRS control as well as to more efficient swine health management overall spreading across diseases, disciplines and technologies."
Boehringer Ingelheim's PRRS franchise has been a market leader in PRRS vaccine segment for more than 10 years. The company achieved more than 1.7 billion doses sold of the franchise in 2020 since Ingelvac® PRRS MLV was launched in 1994 in the US.
The product was approved two years later in Europe.
2015 saw the launch of Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU against PRRSV type 1 infection in the European Union.
Boehringer Ingelheim has sponsored the European PRRS Research Award for 16 years to support applied research for better control of PRRS and more than 48 research projects to support the innovation of PRRS control.
- Boehringer Ingelheim